Imagine Health, Inc.

imaginehealth.com

Imagine Health is an exclusively high quality health plan and provider network delivering better care, a premium experience, and lower costs to its members and their employers. With a network shaped by the industry’s best data-driven methods for identifying the top tier of doctors, hospitals, and specialists, patients see the only the most effective providers. Personalized concierge assistance affords a low-stress experience for members that ensures their families get the right care and understand every step in straightforward terms.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

PRISM BIOLAB, ENTERS MULTI-PROJECT DRUG DISCOVERY COLLABORATION WITH ROCHE AND GENENTECH

PRISM BioLab Co., Ltd. | January 05, 2022

news image

PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Under the terms of the agreement, PRISM BioLab will provide its proprietary library of peptide mimetic small molecules, the PepMetics Library, for screening against targets selected by Roche and Genentech. Upon id...

Read More

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

news image

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More

LEXOGEN AND ONRAMP BIOINFORMATICS PARTNER TO PROVIDE DIFFERENTIAL GENE EXPRESSION DATA ANALYSIS AND INTERPRETATION FOR QUANTSEQ 3' MRNA-SEQ USERS

Lexogen | June 17, 2020

news image

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowle...

Read More
news image

RESEARCH

PRISM BIOLAB, ENTERS MULTI-PROJECT DRUG DISCOVERY COLLABORATION WITH ROCHE AND GENENTECH

PRISM BioLab Co., Ltd. | January 05, 2022

PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Under the terms of the agreement, PRISM BioLab will provide its proprietary library of peptide mimetic small molecules, the PepMetics Library, for screening against targets selected by Roche and Genentech. Upon id...

Read More
news image

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More
news image

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More
news image

LEXOGEN AND ONRAMP BIOINFORMATICS PARTNER TO PROVIDE DIFFERENTIAL GENE EXPRESSION DATA ANALYSIS AND INTERPRETATION FOR QUANTSEQ 3' MRNA-SEQ USERS

Lexogen | June 17, 2020

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowle...

Read More